News & Updates

A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.

Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.

Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with severe eosinophilic asthma, according to a real-world study using patient-level data from RAPSODI*.

In the treatment of children with atopic eczema, ciclosporin is linked to a more rapid response while methotrexate (MTX) is associated with sustained disease control following discontinuation, a study has found.

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

Treatment with sotrovimab does not appear to confer protection against severe forms of COVID-19 in a setting dominated by the Omicron BA.2 subvariant, a study has found.

The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.

In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.